Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

@article{Denmeade2011Phase1A,
  title={Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.},
  author={Samuel R Denmeade and Blair Egerdie and Gary Steinhoff and Rosemina F. Merchant and Ralph J. Abi-Habib and Peter John Pommerville},
  journal={European urology},
  year={2011},
  volume={59 5},
  pages={747-54}
}
BACKGROUND PRX302 is a prostate specific antigen (PSA)-activated pore-forming protein toxin under development as a targeted approach for improving lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) without affecting sexual function. OBJECTIVE To evaluate the safety and efficacy of PRX302 in men with moderate to severe BPH. DESIGN, SETTING, AND PARTICIPANTS Eligible subjects were refractory, intolerant, or unwilling to undergo medical therapies for BPH and had… CONTINUE READING